Novo Nordisk and Bristol Myers Squibb plan nearly 550 New Jersey job cuts as part of global restructuring and cost-saving ...

Over dinner, Samira Shamoon's slim, chic friend let her in on a little secret. She was dabbling with the latest craze backed ...

Eli Lilly (NYSE:LLY) stock has been a huge winner over the past five years, showing gains of more than 400% even when ...

Real-world data showed high incidence of hair loss among GLP-1 receptor agonist users, but the phenomenon is probably an ...

Eli Lilly said its experimental oral GLP-1 drug orforglipron outperformed Novo Nordisk’s oral semaglutide in a head-to-head phase 3 trial. In a 52-week study involving 1,698 adults with Type 2 ...

The New England Journal of Medicine published the results from the OASIS 4 phase 3 trial that studied the efficacy and safety of the ...

This was consistent with previous trial results of injectable Wegovy®.1,3 “The oral semaglutide 25 mg data show compelling ...

A NEW type of fat jab is being trialled on humans for the first time. Inventors claim they can modify RNA genetic material to ...

Novo hopes that because the Wegovy pill has the same active ingredient as the injectable version, regulators and doctors will recognise the broader health benefits of both. Previous trials have found ...

The drug. orforglipron, works on the same receptor as semaglutide (Ozempic/Wegovy), but can be taken without restrictions on food or water intake.

The Trump administration is cracking down on pharmaceutical advertising and they are specifically targeting telehealth ...

Novo Nordisk's experimental Wegovy pill showed a 16.6% weight-loss in a late-stage study, according to data published in The ...